POINT Biopharma Global Inc.
PNT
Cena:
Valuace
53
Růst
0
Zdraví
79
Zprávy
Zahraniční články
Tiskové zprávy
Dokumenty ke stáhnutí
PHEASANT NETWORK BY PG LABS RAISES $2M SEED ROUND TO ACCELERATE AI-POWERED INTENT FOR DEFAI
10-12-2025
TORTOLA, BRITISH VIRGIN ISLANDS--(BUSINESS WIRE)---- $ARB #AI--PHEASANT NETWORK RAISED 2M USD LED BY...
Více zde
AUSTRALIAN DEFENCE SCIENCE AND TECHNOLOGY GROUP SELECTS ADTRAN OPTICAL CESIUM CLOCK FOR PNT RESEARCH
21-08-2025
ADELAIDE, AUSTRALIA--(BUSINESS WIRE)-- #5G--ADTRAN TODAY ANNOUNCED THAT AUSTRALIA'S DEFENCE SCIENCE ...
Více zde
VIAVI LAUNCHES SECOND GENERATION RSR TRANSCODER FOR ASSURED PNT IN GPS-DENIED ENVIRONMENTS
28-05-2025
SOLUTION ENABLES COST-EFFECTIVE RETROFITTING OF LEGACY SYSTEMS WITH INDUSTRY-LEADING PNT RESILIENCE ...
Více zde
ADTRAN DEMONSTRATES OSCILLOQUARTZ ASSURED PNT SOLUTION AT JAMMERTEST
24-10-2024
ANDØYA, NORWAY--(BUSINESS WIRE)-- #5G--ADTRAN TODAY ANNOUNCED THAT ITS OSCILLOQUARTZ TEAM OF NETWOR...
Více zde
ADTRAN AND IRIDIUM STRENGTHEN PNT RESILIENCE IN EUROPE AND ASIA-PACIFIC WITH SATELLITE TIME AND LOCATION TECHNOLOGY
24-06-2024
HUNTSVILLE, ALA.--(BUSINESS WIRE)-- #5G--ADTRAN, IN PARTNERSHIP WITH IRIDIUM COMMUNICATIONS INC. (NA...
Více zde
LILLY COMPLETES ACQUISITION OF POINT BIOPHARMA
27-12-2023
INDIANAPOLIS , DEC. 27, 2023 /PRNEWSWIRE/ -- ELI LILLY AND COMPANY (NYSE: LLY) TODAY ANNOUNCED THE S...
Více zde
LANTHEUS AND POINT BIOPHARMA ANNOUNCE POSITIVE TOPLINE RESULTS FROM PIVOTAL SPLASH TRIAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
18-12-2023
PHASE 3 SPLASH STUDY OF 177LU-PNT2002 DEMONSTRATED STATISTICALLY SIGNIFICANT IMPROVEMENT IN RADIOGRA...
Více zde
LILLY EXTENDS TENDER OFFER TO ACQUIRE POINT BIOPHARMA TO DEC. 22, 2023
18-12-2023
INDIANAPOLIS , DEC. 18, 2023 /PRNEWSWIRE/ -- ELI LILLY AND COMPANY (NYSE: LLY) TODAY ANNOUNCED THE E...
Více zde
LILLY EXTENDS TENDER OFFER TO ACQUIRE POINT BIOPHARMA TO DEC. 15, 2023
04-12-2023
INDIANAPOLIS , DEC. 4, 2023 /PRNEWSWIRE/ -- ELI LILLY AND COMPANY (NYSE: LLY) TODAY ANNOUNCED THE EX...
Více zde
LILLY EXTENDS TENDER OFFER TO ACQUIRE POINT BIOPHARMA TO DEC. 1, 2023
17-11-2023
INDIANAPOLIS , NOV. 17, 2023 /PRNEWSWIRE/ -- ELI LILLY AND COMPANY (NYSE: LLY) TODAY ANNOUNCED THE E...
Více zde
LILLY ANNOUNCES THE RECEIPT OF NRC CONSENT IN CONNECTION WITH ITS PROPOSED ACQUISITION OF POINT BIOPHARMA
14-11-2023
INDIANAPOLIS , NOV. 14, 2023 /PRNEWSWIRE/ -- ELI LILLY AND COMPANY (NYSE: LLY) TODAY ANNOUNCED THAT ...
Více zde
POINT BIOPHARMA REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS
13-11-2023
ANNOUNCED A DEFINITIVE AGREEMENT TO BE ACQUIRED BY LILLY FOR A PURCHASE PRICE OF $12.50 PER SHARE IN...
Více zde
LILLY ANNOUNCES EXTENSION OF TENDER OFFER TO ACQUIRE POINT BIOPHARMA
08-11-2023
INDIANAPOLIS , NOV. 8, 2023 /PRNEWSWIRE/ -- ELI LILLY AND COMPANY (NYSE: LLY) TODAY ANNOUNCED THE E...
Více zde
POINT BIOPHARMA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF POINT BIOPHARMA GLOBAL, INC. - PNT
06-10-2023
NEW ORLEANS--(BUSINESS WIRE)--FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ. AND TH...
Více zde
SHAREHOLDER ALERT: ADEMI LLP INVESTIGATES WHETHER POINT BIOPHARMA GLOBAL, INC. HAS OBTAINED A FAIR PRICE IN ITS TRANSACTION WITH ELI LILLY
03-10-2023
MILWAUKEE , OCT. 3, 2023 /PRNEWSWIRE/ -- ADEMI LLP IS INVESTIGATING POINT (NASDAQ: PNT) FOR POSSIBLE...
Více zde
LILLY TO ACQUIRE POINT BIOPHARMA TO EXPAND ONCOLOGY CAPABILITIES INTO NEXT-GENERATION RADIOLIGAND THERAPIES
03-10-2023
INDIANAPOLIS , OCT. 3, 2023 /PRNEWSWIRE/ -- ELI LILLY AND COMPANY (NYSE: LLY) AND POINT BIOPHARMA ...
Více zde
POINT BIOPHARMA REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS
14-08-2023
ENROLLMENT IN PNT2002'S SPLASH TRIAL IS COMPLETE AND TOPLINE DATA IS EXPECTED IN THE FOURTH QUARTER ...
Více zde
ITM AND POINT BIOPHARMA EXPAND GLOBAL SUPPLY AGREEMENT FOR N.C.A. LUTETIUM-177
31-07-2023
GARCHING / MUNICH, GERMANY AND INDIANAPOLIS, JULY 31, 2023 (GLOBE NEWSWIRE) -- ITM ISOTOPE TECHNOLOG...
Více zde
POINT BIOPHARMA AND ADVANCELL TO COLLABORATE IN THE DEVELOPMENT OF LEAD-212-LABELED RADIOLIGANDS
26-06-2023
POINT'S VERTICALLY INTEGRATED PLATFORM TOGETHER WITH ADVANCELL'S LEAD-212 (²¹²PB) GENERATOR TECHN...
Více zde
POINT BIOPHARMA EXPANDS ITS RESEARCH WITH NEXT-GENERATION ISOTOPES, PUBLISHING NEW PRECLINICAL DATA AT SNMMI'S ANNUAL CONGRESS
26-06-2023
AUGER ELECTRON AND BETA EMITTING ISOTOPE TERBIUM-161 WAS PAIRED WITH POINT'S FAP-TARGETED PNT6555 LI...
Více zde
POINT BIOPHARMA TO HOST VIRTUAL INVESTOR DAY ON TUESDAY, JUNE 20, 2023
07-06-2023
REGISTER ONLINE TODAY AT: HTTPS://HUB.POINTBIOPHARMA.COM/INVESTOR-DAY-JUNE-2023...
Více zde
POINT BIOPHARMA ANNOUNCES FRONTIER TRIAL-IN-PROGRESS POSTER PRESENTATION AT ASCO
25-05-2023
PNT2004 PROGRAM'S PHASE 1 FRONTIER TRIAL DESIGN TO BE PRESENTED ABSTRACT TO BE RELEASED TODAY AT 5:0...
Více zde
POINT BIOPHARMA MAKES STRATEGIC INVESTMENT IN COMMERCIAL-SCALE ALPHA-EMITTING ISOTOPE MANUFACTURER
15-05-2023
POINT FURTHER STRENGTHENS SUPPLY CHAIN WITH $10 MILLION INVESTMENT IN IONETIX ALPHA CORP. POINT FURT...
Více zde
POINT BIOPHARMA REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS
15-05-2023
U.S. FDA GRANTED FAST TRACK DESIGNATION FOR 177 LU-PNT2002 FOR THE TREATMENT OF MCRPC IN APRIL 2023...
Více zde
LANTHEUS AND POINT BIOPHARMA ANNOUNCE FDA GRANTS FAST TRACK DESIGNATION FOR 177LU-PNT2002 FOR THE TREATMENT OF METASTATIC CASTRATION RESISTANT PROSTATE CANCER
24-04-2023
BEDFORD, MASS. AND INDIANAPOLIS, APRIL 24, 2023 (GLOBE NEWSWIRE) -- LANTHEUS HOLDINGS, INC. (“LANT...
Více zde
POINT BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS AND PROVIDES BUSINESS HIGHLIGHTS
27-03-2023
SIGNED STRATEGIC COLLABORATION AGREEMENT WITH LANTHEUS HOLDINGS INC. FOR POINT'S PNT2002 AND PNT2003...
Více zde
POINT BIOPHARMA CONFIRMS NO DISRUPTIONS TO THE MANUFACTURING AND CLINICAL SUPPLY FOR THE 177LU-PNT2002 SPLASH TRIAL, A PHASE 3 STUDY IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC)
07-03-2023
INDIANAPOLIS, MARCH 07, 2023 (GLOBE NEWSWIRE) -- POINT BIOPHARMA GLOBAL INC. (NASDAQ: PNT) (THE “C...
Více zde
POINT BIOPHARMA TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
02-02-2023
INDIANAPOLIS, FEB. 02, 2023 (GLOBE NEWSWIRE) -- POINT BIOPHARMA GLOBAL INC. (NASDAQ: PNT) (THE “CO...
Více zde
POINT BIOPHARMA COMPLETES RANDOMIZATION IN PNT2002'S PHASE 3 SPLASH TRIAL
12-01-2023
ENROLLMENT FOR THE RANDOMIZATION PHASE OF SPLASH COMPLETED PRIOR TO EOY 2022, MEETING PREVIOUS GUIDA...
Více zde
POINT BIOPHARMA ANNOUNCES CLOSING OF AGREEMENTS WITH LANTHEUS HOLDINGS
20-12-2022
INDIANAPOLIS, DEC. 20, 2022 (GLOBE NEWSWIRE) -- POINT BIOPHARMA GLOBAL INC. (“POINT”) (NASDAQ: P...
Více zde
| Datum | Typ | Otevřít EDGAR | Stáhnout dokument |
|---|---|---|---|
| 2023-12-27 00:00:00 | 8-K |  | Stáhnout |
| 2023-12-26 23:00:00 | 8-K | | Stáhnout |
| 2023-11-13 00:00:00 | 10-Q | | Stáhnout |
| 2023-11-12 23:00:00 | 10-Q | | Stáhnout |
| 2023-10-03 01:00:00 | 8-K | | Stáhnout |
| 2023-10-03 00:00:00 | 8-K | | Stáhnout |
| 2023-08-14 01:00:00 | 8-K | | Stáhnout |
| 2023-08-14 01:00:00 | 10-Q | | Stáhnout |
| 2023-08-14 00:00:00 | 8-K | | Stáhnout |
| 2023-08-14 00:00:00 | 10-Q | | Stáhnout |
| 2023-08-03 01:00:00 | 8-K | | Stáhnout |
| 2023-08-03 00:00:00 | 8-K | | Stáhnout |
| 2023-06-13 01:00:00 | 8-K | | Stáhnout |
| 2023-06-13 00:00:00 | 8-K | | Stáhnout |
| 2023-06-05 01:00:00 | 8-K | | Stáhnout |
| 2023-06-05 00:00:00 | 8-K | | Stáhnout |
| 2023-05-15 01:00:00 | 10-Q | | Stáhnout |
| 2023-05-15 00:00:00 | 10-Q | | Stáhnout |
| 2023-03-27 01:00:00 | 10-K | | Stáhnout |
| 2023-03-27 00:00:00 | 10-K | | Stáhnout |
| 2023-02-07 00:00:00 | 8-K | | Stáhnout |
| 2023-02-06 23:00:00 | 8-K | | Stáhnout |
| 2022-11-14 00:00:00 | 10-Q | | Stáhnout |
| 2022-11-13 23:00:00 | 10-Q | | Stáhnout |
| 2022-09-14 01:00:00 | 8-K | | Stáhnout |
| 2022-09-14 00:00:00 | 8-K | | Stáhnout |
| 2022-09-13 01:00:00 | 8-K | | Stáhnout |
| 2022-09-13 00:00:00 | 8-K | | Stáhnout |
| 2022-09-12 01:00:00 | 8-K | | Stáhnout |
| 2022-09-12 00:00:00 | 8-K | | Stáhnout |
| 2022-09-06 01:00:00 | 8-K | | Stáhnout |
| 2022-09-06 00:00:00 | 8-K | | Stáhnout |
| 2022-08-12 01:00:00 | 10-Q | | Stáhnout |
| 2022-08-12 00:00:00 | 10-Q | | Stáhnout |
| 2022-06-03 01:00:00 | 8-K | | Stáhnout |
| 2022-06-03 00:00:00 | 8-K | | Stáhnout |
| 2022-05-16 01:00:00 | 8-K | | Stáhnout |
| 2022-05-16 00:00:00 | 8-K | | Stáhnout |
| 2022-05-13 01:00:00 | 10-Q | | Stáhnout |
| 2022-05-13 00:00:00 | 10-Q | | Stáhnout |
| 2022-05-12 01:00:00 | 8-K | | Stáhnout |
| 2022-05-12 00:00:00 | 8-K | | Stáhnout |
| 2022-03-25 00:00:00 | 8-K | | Stáhnout |
| 2022-03-25 00:00:00 | 10-K | | Stáhnout |
| 2022-03-24 23:00:00 | 8-K | | Stáhnout |
| 2022-03-24 23:00:00 | 10-K | | Stáhnout |
| 2022-02-25 00:00:00 | 8-K | | Stáhnout |
| 2022-02-24 23:00:00 | 8-K | | Stáhnout |
| 2022-02-15 00:00:00 | 8-K | | Stáhnout |
| 2022-02-14 23:00:00 | 8-K | | Stáhnout |
| 2021-12-10 00:00:00 | 8-K | | Stáhnout |
| 2021-12-09 23:00:00 | 8-K | | Stáhnout |
| 2021-12-01 00:00:00 | 8-K | | Stáhnout |
| 2021-11-30 23:00:00 | 8-K | | Stáhnout |
| 2021-11-19 00:00:00 | 8-K | | Stáhnout |
| 2021-11-18 23:00:00 | 8-K | | Stáhnout |
| 2021-11-12 00:00:00 | 10-Q | | Stáhnout |
| 2021-11-11 23:00:00 | 10-Q | | Stáhnout |
| 2021-09-28 01:00:00 | 8-K | | Stáhnout |
| 2021-09-28 00:00:00 | 8-K | | Stáhnout |
| 2021-08-13 01:00:00 | 8-K | | Stáhnout |
| 2021-08-13 01:00:00 | 10-Q | | Stáhnout |
| 2021-08-13 00:00:00 | 8-K | | Stáhnout |
| 2021-08-13 00:00:00 | 10-Q | | Stáhnout |
| 2021-07-01 01:00:00 | 8-K | | Stáhnout |
| 2021-07-01 00:00:00 | 8-K | | Stáhnout |
| 2021-06-30 01:00:00 | 8-K | | Stáhnout |
| 2021-06-30 00:00:00 | 8-K | | Stáhnout |
| 2021-06-21 01:00:00 | 8-K | | Stáhnout |
| 2021-06-21 00:00:00 | 8-K | | Stáhnout |
| 2021-06-09 01:00:00 | 8-K | | Stáhnout |
| 2021-06-09 00:00:00 | 8-K | | Stáhnout |
| 2021-06-04 01:00:00 | 8-K | | Stáhnout |
| 2021-06-04 00:00:00 | 8-K | | Stáhnout |
| 2021-06-01 01:00:00 | 8-K | | Stáhnout |
| 2021-06-01 00:00:00 | 8-K | | Stáhnout |
| 2021-04-29 01:00:00 | 10-Q | | Stáhnout |
| 2021-04-29 00:00:00 | 10-Q | | Stáhnout |
| 2021-04-28 01:00:00 | 8-K | | Stáhnout |
| 2021-04-28 00:00:00 | 8-K | | Stáhnout |
| 2021-03-15 00:00:00 | 8-K | | Stáhnout |
| 2021-03-14 23:00:00 | 8-K | | Stáhnout |
| 2021-03-04 00:00:00 | 10-K | | Stáhnout |
| 2021-03-03 23:00:00 | 10-K | | Stáhnout |
| 2020-11-02 00:00:00 | 10-Q | | Stáhnout |
| 2020-11-01 23:00:00 | 10-Q | | Stáhnout |
| 2020-08-20 01:00:00 | 10-Q | | Stáhnout |
| 2020-08-20 00:00:00 | 10-Q | | Stáhnout |
| 2020-08-06 01:00:00 | 8-K | | Stáhnout |
| 2020-08-06 00:00:00 | 8-K | | Stáhnout |
| 2020-07-16 01:00:00 | 8-K | | Stáhnout |
| 2020-07-16 00:00:00 | 8-K | | Stáhnout |
| 2020-07-10 01:00:00 | 8-K | | Stáhnout |
| 2020-07-10 00:00:00 | 8-K | | Stáhnout |
